Zelira Therapeutics Ltd has released a press release.
Appendix 4D & FY23 Interim Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- Zelira Executive Director Appointed
- ZLD secures US$8.6 million funding for HOPE 1 US FDA trials
- December 2022 Quarterly Activities Report
- Zelira receives $1.14 million cash R&D Tax Incentive
- ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial
Later from Zelira Therapeutics
- Zelira raises A$1.77 million from US-based investors
- March 2023 Quarterly Activities Report
- ZLD secures additional US$3.25M investment in HOPE SPV
- Trading Halt
- Zeliras diabetic nerve pain drug outperforms Lyrica
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics